KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.Rheumatology (Oxford)PMID 33822898PMC85662002021-Nov-030.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.Clin Infect DisPMID 33119068PMC85632022021-Nov-020.98未发现恶性肿瘤人群证据。待处理
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.Hum Vaccin ImmunotherPMID 34406911PMC88281602021-Nov-020.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants.Hum Vaccin ImmunotherPMID 34428112PMC88281172021-Nov-020.98未发现恶性肿瘤人群证据。待处理
Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.Hum Vaccin ImmunotherPMID 34499574PMC88281102021-Nov-020.98未发现恶性肿瘤人群证据。待处理
Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 33901566无 PMCID2021-Nov-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.Int J Radiat Oncol Biol PhysPMID 34102298无 PMCID2021-Nov-010.95The record describes a phase 3 randomized trial evaluating a drug intervention (topical steroid) in an oncology setting, but the primary efficacy endpoint is the frequency (incidence) of radiation dermatitis, which is a categorical toxicity outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). No time-to-event analysis (Kaplan-Meier, HR) is mentioned. Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint.待处理
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.J Clin OncolPMID 34228505无 PMCID2021-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.J Clin OncolPMID 34310172PMC85479232021-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.JAMA CardiolPMID 34319398PMC85765872021-Nov-010.98未发现恶性肿瘤人群证据。待处理
Phase 3 Trials of Enhanced Versus Usual Care Physical Therapy for Patients at Risk of Poor Outcome Following Knee Arthroplasty: A Perspective on Meaning and a Way Forward.Phys TherPMID 34331766PMC85653322021-Nov-010.98未发现恶性肿瘤人群证据。待处理
Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study.Am J HematolPMID 34370319无 PMCID2021-Nov-010.85Eligible study meets oncology, human, randomized, Phase III, time-to-event, and original result criteria, but is excluded because it lacks a drug intervention. The study evaluates donor selection hierarchies for stem cell transplantation, which is a procedure/transplant intervention, not a pharmacological drug therapy as required for inclusion.待处理
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.Clin Cancer ResPMID 34380637PMC94015092021-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.Clin Cancer ResPMID 34380643PMC94015172021-Nov-010.98未发现恶性肿瘤人群证据。待处理
Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.Am J HematolPMID 34390504无 PMCID2021-Nov-010.85The study is a randomized Phase III trial with time-to-event endpoints, but the intervention (low-dose thymoglobulin) is an immunosuppressive agent for preventing graft-versus-host disease, not a drug for treating the underlying cancer (acute leukemia). Therefore, it does not meet the required drug intervention criterion for an oncology Kaplan-Meier cohort.待处理
Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education.J Clin OncolPMID 34406839PMC85479162021-Nov-010.85The study is a randomized, Phase III clinical trial in breast cancer survivors with a primary efficacy endpoint of change in depressive symptoms. It does not involve a drug-containing intervention (interventions are mindfulness meditation and survivorship education) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).待处理
Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.Pediatr Infect Dis JPMID 34533489PMC85051552021-Nov-010.98未发现恶性肿瘤人群证据。待处理
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.JAMA OncolPMID 34554208PMC84615522021-Nov-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma.Asian Pac J Cancer PrevPMID 34837931PMC90681802021-Nov-010.95The study is a randomized, phase III oncology trial with a drug intervention and reports primary efficacy results, but the key endpoint is a non-time-to-event outcome (severity of oral mucositis), failing the time-to-event criterion required for Kaplan-Meier digitization.待处理
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.Diabetes Obes MetabPMID 34263971无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study.Dig EndoscPMID 33527576PMC85967312021-Nov0.98未发现恶性肿瘤人群证据。待处理
Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.J RheumatolPMID 33858976无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.Arthritis RheumatolPMID 33913260PMC85969292021-Nov0.98未发现恶性肿瘤人群证据。待处理
Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double-blind placebo-controlled trial.BJOGPMID 33982872无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.Lancet Respir MedPMID 34153272无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.CephalalgiaPMID 34171973PMC85920992021-Nov0.98未发现恶性肿瘤人群证据。待处理
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.OncologistPMID 34213061PMC85717732021-Nov0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.Lancet Respir MedPMID 34214475无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.Mov DisordPMID 34236101PMC92927742021-Nov0.98未发现恶性肿瘤人群证据。待处理
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.J Thorac OncolPMID 34265434无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.Future OncolPMID 34269067无 PMCID2021-Nov0.45The record describes a Phase III, randomized, drug-intervention trial in esophageal cancer, meeting core oncology, human, randomization, and phase criteria. However, the title and abstract do not explicitly report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) nor present Kaplan-Meier curves or hazard ratios. The document is identified as a protocol/rationale ('study described here'), not a formal result report. Therefore, is_eligible is set to null due to insufficient evidence for the time_to_event and original_result criteria.待处理
The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.Clin Pharmacol TherPMID 34270797PMC92908542021-Nov0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.Future OncolPMID 34278827PMC85301532021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial.Int Urol NephrolPMID 34292493PMC84947012021-Nov0.98未发现恶性肿瘤人群证据。待处理
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.Eur J NeurolPMID 34292643PMC92918722021-Nov0.98未发现恶性肿瘤人群证据。待处理
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.OncologistPMID 34313371PMC85717422021-Nov0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.Cancer SciPMID 34327766PMC85866802021-Nov0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.Clin Lymphoma Myeloma LeukPMID 34334330PMC85686622021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset.Acta OncolPMID 34355650无 PMCID2021-Nov0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.Gastric CancerPMID 34363528PMC85021402021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.Clin Lymphoma Myeloma LeukPMID 34389273PMC94076802021-Nov0.80The study is a Phase III randomized oncology trial in humans with a drug intervention, but it reports only safety run-in results and objective response rates (ORR), not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort.待处理
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.Ann HematolPMID 34398258PMC85109042021-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.J Inherit Metab DisPMID 34418116PMC92930142021-Nov0.98未发现恶性肿瘤人群证据。待处理
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).Future OncolPMID 34423676无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial.Lancet Respir MedPMID 34454654无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).Eur J CancerPMID 34464782无 PMCID2021-Nov1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).Eur J CancerPMID 34507244无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.Am J Clin DermatolPMID 34515985PMC84368722021-Nov0.98未发现恶性肿瘤人群证据。待处理
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).Gynecol OncolPMID 34521554无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.Adv TherPMID 34542830PMC85230042021-Nov0.98未发现恶性肿瘤人群证据。待处理